Rigel Pharmaceuticals, Inc. (RIGL) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Wait for pullback to $37.00. At $38.75 the A.R:R is 1.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $37.00 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Earnings expected to decline ~75% (cyclical peak); Consecutive earnings misses (2).
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult... Read more
Wait for pullback to $37.00. At $38.75 the A.R:R is 1.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $37.00 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Earnings expected to decline ~75% (cyclical peak); Consecutive earnings misses (2). Chart setup: Death cross but MACD improving, RSI 79. Wide-moat business. Accumulate on weakness. Score 6.1/10, moderate confidence.
Passes 8/10 gates (positive momentum, clean insider activity, positive momentum, no SEC red flags, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — Rigel Pharmaceuticals, Inc.
Latest news
- NEWS Rigel Pharmaceuticals Appoints Dr. Alison L. Hannah as CMO (RIGL) - GuruFocus — GuruFocus positive
- NEWS RIGL Q1 2026 Earnings: EPS Misses Estimates Despite Strong Quarter, Stock Edges Higher - High Growth Earnings - dars.gov — dars.gov.et negative
- NEWS Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com — marketscreener.com positive
- NEWS Rigel Pharmaceuticals, Inc.(NasdaqGS: RIGL) added to Russell 3000 Value Benchmark - marketscreener.com — marketscreener.com positive
- NEWS Rigel Pharmaceuticals, Inc.(NasdaqGS: RIGL) added to Russell 2000 Value Benchmark - marketscreener.com — marketscreener.com positive
Generated 2026-07-05T09:50:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $37.00. At $38.75 the A.R:R is 1.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $37.00 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Earnings expected to decline ~75% (cyclical peak); Consecutive earnings misses (2). Chart setup: Death cross but MACD improving, RSI 79. Wide-moat business. Accumulate on weakness. Target $47.15 (+21.7%), stop $34.41 (−12.6%), A.R:R 1.4:1. Score 6.1/10, moderate confidence.
Take-profit target: $47.15 (+27.4% upside). Target $47.15 (+21.7%), stop $34.41 (−12.6%), A.R:R 1.4:1. Stop-loss: $34.41.
Earnings expected to decline ~75% (cyclical peak); Consecutive earnings misses (2); Weak growth.
Rigel Pharmaceuticals, Inc. trades at a P/E of 2.0 (forward 8.1). TrendMatrix value score: 8.8/10. Verdict: Buy (Wait for Entry).
11 analysts cover RIGL with a consensus score of 4.1/5. Average price target: $54.
What does Rigel Pharmaceuticals, Inc. do?Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of...
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.